These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22807330)

  • 1. Ribonucleoside 3'-phosphates as pro-moieties for an orally administered drug.
    Palte MJ; Davis AK; McGrath NA; Spiegel CA; Raines RT
    ChemMedChem; 2012 Aug; 7(8):1361-4. PubMed ID: 22807330
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of Bacteroides fragilis resistance to metronidazole.
    Ghotaslou R; Bannazadeh Baghi H; Alizadeh N; Yekani M; Arbabi S; Memar MY
    Infect Genet Evol; 2018 Oct; 64():156-163. PubMed ID: 29936037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteroides fragilis resistant to metronidazole after long-term therapy.
    Ingham HR; Eaton S; Venables CW; Adams PC
    Lancet; 1978 Jan; 1(8057):214. PubMed ID: 74641
    [No Abstract]   [Full Text] [Related]  

  • 4. Bacteraemia due to Bacteroides fragilis with reduced susceptibility to metronidazole.
    Elsaghier AA; Brazier JS; James EA
    J Antimicrob Chemother; 2003 Jun; 51(6):1436-7. PubMed ID: 12746378
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhanced pathogenicity of susceptible strains of the Bacteroides fragilis group subjected to low doses of metronidazole.
    Diniz CG; Arantes RM; Cara DC; Lima FL; Nicoli JR; Carvalho MA; Farias LM
    Microbes Infect; 2003 Jan; 5(1):19-26. PubMed ID: 12593969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronidazole resistant Bacteroides fragilis infection of a prosthetic hip joint.
    Hickey MM; Davies UM; Dave J; Vogler M; Wall RA
    J Infect; 1990 Mar; 20(2):129-33. PubMed ID: 2319145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.
    Goldstein EJ; Citron DM; Tyrrell KL; Leoncio ES; Merriam CV
    Anaerobe; 2017 Feb; 43():1-3. PubMed ID: 27713022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bacteriological and clinical studies on metronidazole in Bacteroides fragilis infections (author's transl)].
    Shimada K; Inamatsu T; Sato K
    Jpn J Antibiot; 1979 Feb; 32(2):191-4. PubMed ID: 439390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteroides fragilis meningitis successfully treated with metronidazole after a previous failure with thiamphenicol.
    Soriano F; Aguado JM; Tornero J; Fernandez-Guerrero ML; Gómez-Garcés JL
    J Clin Microbiol; 1986 Sep; 24(3):472-3. PubMed ID: 3760141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
    Bartlett JG; Dezfulian M; Joiner K
    Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative antibacterial efficacy of clindamycin and metronidazole against Bacteroides fragilis in vitro and in experimentally infected mice.
    Dijkmans BA; Vaishnav J; Mattie H
    Chemotherapy; 1985; 31(4):297-303. PubMed ID: 4028873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antibiotics on the prevention of experimental Bacteroides fragilis endocarditis.
    Goldman PL; Durack DT; Petersdorf RG
    Antimicrob Agents Chemother; 1978 Nov; 14(5):755-60. PubMed ID: 727764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronidazole treatment of Bacteroides fragilis infections.
    Melo JC; Raff MJ; Wunderlich HF; Chun CH; Summersgill JT; Varghese R
    Am J Med Sci; 1980; 280(3):143-9. PubMed ID: 7457495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance in the Bacteroides fragilis group in faecal microbiota from healthy Danish children.
    Sydenham TV; Jensen BH; Petersen AM; Krogfelt KA; Justesen US
    Int J Antimicrob Agents; 2017 May; 49(5):573-578. PubMed ID: 28366659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Appearance of metronidazole resistance in Bacteroides fragilis].
    Chardon H; Ratignier A; Luneau R; Garrigues B
    Nouv Presse Med; 1977 Jun; 6(24):2165. PubMed ID: 905136
    [No Abstract]   [Full Text] [Related]  

  • 17. Bacteroides fragilis resistant to both metronidazole and imipenem.
    Lamothe F; Fijalkowski C; Malouin F; Bourgault AM; Delorme L
    J Antimicrob Chemother; 1986 Nov; 18(5):642-3. PubMed ID: 3468099
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
    Betriu C; Culebras E; Gómez M; López F; Rodríguez-Avial I; Picazo JJ
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2686-90. PubMed ID: 18474575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular study on metronidazole resistance in Bacteroides fragilis group isolates from a South Indian tertiary care center.
    Jahan L; Biswas R
    Anaerobe; 2023 Apr; 80():102692. PubMed ID: 36642289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
    Thadepalli H; Chuah SK; Gollapudi S
    Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.